Eton Pharmaceuticals (ETON) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Septerna (SEPN) over the past year, gaining 161.6% versus a gain of 71.3%. Septerna is the larger company by market cap ($1.72 billion vs $1.56 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | SEPN |
|---|---|---|
| Share price | $54.75 | $36.90 |
| Market cap | $1.56B | $1.72B |
| 1-day change | -0.24% | +2.50% |
| YTD return | +223.77% | +29.12% |
| 1-year return | +161.59% | +71.35% |
| 5-year return | +953.36% | — |
| P/E ratio (TTM) | 136.88 | — |
| Forward P/E | 21.22 | — |
| EPS (TTM) | $0.40 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $66.37 | $51.10 |
| 52-week low | $14.27 | $17.55 |
| Distance from 52-week high | -17.51% | -27.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.68% | +46.94% |
| Average volume | 606.07K | 393.97K |
| Shares outstanding | 28.58M | 46.68M |
| Employees | 44 | 123 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed SEPN by 90.2 percentage points over the past year.
- The two companies sit in different sectors: Eton Pharmaceuticals in Healthcare and Septerna in Health Care.
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Healthcare · Drug Manufacturers - Specialty & Generic · 44 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
ETON vs SEPN FAQ
Which is bigger, Eton Pharmaceuticals or Septerna?
Septerna (SEPN) is larger, with a market capitalization of $1.72B compared with $1.56B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ETON or SEPN?
ETON returned +161.59% over the past 12 months, compared with +71.35% for SEPN (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Septerna in the same industry?
No. Eton Pharmaceuticals is in the Healthcare sector, while Septerna is in Health Care.